Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy
- 8 March 2012
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 42 (7), 627-636
- https://doi.org/10.1111/j.1872-034x.2012.00998.x
Abstract
With the increasing use of potent immunosuppressive therapy, reactivation of hepatitis B virus (HBV) in endemic regions is becoming a clinical problem requiring special attention. A recent annual nationwide survey clarified that HBV reactivation related to immunosuppressive therapy has been increasing in patients with malignant lymphoma, other hematological malignancies, oncological or rheumatological disease. In the survey, rituximab plus steroid-containing chemotherapy was identified as a risk factor for HBV reactivation in hepatitis B surface antigen (HBsAg) negative patients with malignant lymphoma. In this setting, HBV reactivation resulted in fatal fulminant hepatitis regardless of the treatment of nucleoside analog. The Intractable Hepatobiliary Disease Study Group and the Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis jointly developed guidelines for preventing HBV reactivation. The essential features of the guideline are as follows. All patients should be screened for HBsAg by a sensitive method before the start of immunosuppressive therapy. Second, hepatitis B core antigen (HBcAb) and hepatitis B surface antibody (HBsAb) testing should be performed in HBsAg negative patients, especially those receiving intensive immunosuppressive therapy. Prophylaxis with nucleoside analogs is essential for preventing HBV reactivation in HBsAg positive patients. In contrast, HBsAg negative with HBcAb and/or HBsAb positive patients should be monitored monthly for an increase in serum HBV DNA during and 12 months after completion of chemotherapy. Nucleoside analogs should be administrated immediately when HBV DNA becomes positive during this period. This strategy facilitates commencement of nucleoside analogs at an early stage of HBV reactivation and results in prevention of severe hepatitis.Keywords
This publication has 72 references indexed in Scilit:
- Chronic hepatitis B: Update 2009Hepatology, 2009
- Evaluation of the patient with hepatitis BHepatology, 2009
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyHepatology, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximabThe Esophagus, 2008
- A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trialHepatology, 2007
- Spontaneous relapse of hepatitis in inactive HBsAg carriersHepatology International, 2007
- Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions PresentAntimicrobial Agents and Chemotherapy, 2007
- Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor regionEuropean Journal of Haematology, 2006
- Persistence of hepatitis B virus DNA after serological clearance of hepatitis B virusLiver International, 1990